(Abstracted from Ultrasound Obstet Gynecol 2018;51:738–742)
The current approach to screening for preeclampsia (PE) is to identify risk factors from maternal demographic characteristics and medical history (maternal factors). According to the National Institute for Health and Care Excellence (NICE), in the United Kingdom, women are considered to be at high risk of developing PE if they have any one high-risk factor (hypertensive disease in previous pregnancy, chronic hypertension, chronic renal disease, diabetes mellitus, or autoimmune disease) or any 2 moderate-risk factors (nulliparity, age ≥40 years, body mass index [BMI] ≥35 kg/m2, family history of PE, or interpregnancy interval >10 years).
King's College London, London, United Kingdom (L.C.P.); Chinese University of Hong Kong, Hong Kong, China (L.C.P.); King's College Hospital, London (D.L.R., M.Y.T., T.T., R.A., M.S., W.A., T.E., K.H.N.); Lewisham University Hospital, London (M.Y.T.), United Kingdom; Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain (J.L.D.); North Middlesex University Hospital, London (T.T.); Medway Maritime Hospital, Gillingham (R.A.); Southend University Hospital, Essex (M.S.); Homerton University Hospital, London (T.E.), United Kingdom; University Hospital Brugmann, Université Libre de Bruxelles, Brussels, Belgium (J.C.J.); Hospiten Group, Tenerife, Canary Islands, Spain (W.P.); Attikon University Hospital, Athens, Greece (G.P.); Hospital Universitario San Cecilio, Granada, Spain (A.R.B.); Ospedale Maggiore Policlinico, Milan, Italy (I.F.C.); and University of Exeter, Exeter, United Kingdom (D.W.)